A Hidden Killer and Why Patients Face Barriers to Accessing Promising New Drugs for It
April 12, 201818m 5s
Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Familial hypercholesterolemia, or FH, is an inherited disorder that leads to premature cardiovascular disease. It can lead to heart attacks, strokes, and the narrowing of heart valves. In people with the condition, genetic mutations impair the ability of the liver to metabolize excess fats. While an estimated 1.3 million people in the United States have FH, only about 10 percent are diagnosed. We spoke to Katherine Wilemon, founder and CEO of the FH Foundation, about the condition, why so many people are undiagnosed, and why patients face significant barriers getting access to a new class of promising drugs to treat the condition.